Search results
Oppenheimer raises Deere shares target, cites cautious market view By Investing.com
Investing.com· 3 hours agoOn Friday, Oppenheimer maintained a positive outlook on Deere & Company (NYSE:DE) shares, raising...
Meet the Cast of “IF”: All the Stars Voicing Characters, from Blake Lively to Steve Carell
People via Yahoo News· 1 hour agoIt was a family affair," Krasinski said. While Blunt is well-known for her roles in The Devil Wears...
John Krasinski Shares How His Kids’ Imaginary Friends Inspired the Family Movie “IF” (Exclusive)
People via Yahoo News· 2 hours agoKrasinski, 44, recalls being at home and watching Hazel, 10, and Violet, 7, the girls he shares with...
Is ORNAX a Strong Bond Fund Right Now?
Zacks via Yahoo Finance· 3 hours agoIf investors are looking at the Muni - Bonds fund category, Oppenheimer Rochester High Yield Municipals A (ORNAX) could be a potential option. ORNAX has...
Nvidia is seeing ‘insatiable’ demand, but these are the key questions
Market Watch· 16 minutes agoOnce again, investors will look long-term when Nvidia Corp. reports results next week. when it...
Take-Two’s New ‘Grand Theft Auto’ Will Land in Fall 2025. The Stock Drops.
Barrons.com· 2 hours agoShares of Take-Two were down 2.5% to $142.98 in early trading. Coming into the session, the stock...
Confluent (NASDAQ:CFLT) Coverage Initiated by Analysts at Oppenheimer
ETF DAILY NEWS· 6 hours agoResearch analysts at Oppenheimer assumed coverage on shares of Confluent (NASDAQ:CFLT – Get Free...
Insider Selling: CEO Matthew Oppenheimer Sells 20,832 Shares of Remitly Global Inc (RELY)
GuruFocus.com via Yahoo Finance· 1 day agoOn May 14, 2024, Matthew Oppenheimer, the Chief Executive Officer of Remitly Global Inc...
Robinhood upgraded, Baidu downgraded: Wall Street's top analyst calls
The Fly via Yahoo Finance· 47 minutes agoThe firm says the company has made good progress in its turnaround story, evidenced by two...
Oppenheimer Cuts UroGen Pharma (NASDAQ:URGN) Price Target to $32.00
ETF DAILY NEWS· 1 day agoUroGen Pharma (NASDAQ:URGN – Get Free Report) had its price objective lowered by Oppenheimer from $34.00 to $32.00 in a research report issued on Tuesday, Benzinga reports ...